GSK is to invest up to $800 million in new facilities which will focus on drug substance manufacturing and additional drug product manufacturing capabilities at its site in Marietta, Pennsylvania, representing the company’s largest US manufacturing investment.

The new multi-purpose facility will be capable of manufacturing sterile liquid vaccines and medicines, and will also house a state-of-the-art R&D pilot plant to manufacture medicines for clinical trials. Additionally, GSK will establish a new vaccines drug substance facility at the site, dedicated to manufacturing products based on the company’s novel MAPS technology, subsequent to future regulatory submissions and approvals. This expansion will double the size and capacity of the Marietta site, and construction of the new facilities is expected to start by the end of this year. The drug substance facility is anticipated to be operational by the end of 2027, with the drug product facility following by the end of 2028.